Tags

Type your tag names separated by a space and hit enter

[Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
Ned Tijdschr Geneeskd. 2004 Oct 09; 148(41):2021-5.NT

Abstract

OBJECTIVE

To assess the side effects, safety and efficacy of highly active antiretroviral therapy (HAART) in a cohort of HIV-infected pregnant women in the Netherlands.

DESIGN

Retrospective.

METHOD

Data were collected from the medical records of HIV-infected pregnant women who received HAART during pregnancy in the period 1 January 1997-1 June 2003 at 14 HIV-specialized centres in the Netherlands. The inclusion criteria were at least a triple drug regimen and birth at 20 or more weeks of gestation. Information was collected about patient characteristics, HAART prescribed, side effects, viral load response, mode of delivery and HIV-status of the neonate.

RESULTS

A total of 267/413 women satisfied the inclusion criteria. Most women (n = 199) had not previously received anti-retroviral therapy and started HAART between weeks 21 and 28 of the pregnancy. The two most frequently used regimens contained nelfinavir (57%) or nevirapine (31%). Gastrointestinal side effects were more frequently observed in the nelfinavir group, while rash and hepatotoxicity were more frequently reported in the nevirapine group. Efficacy and pregnancy outcome were similar in both groups. Two infants (0.7%) were HIV-infected.

CONCLUSION

HAART regimens containing nelfinavir or nevirapine in HIV-infected pregnant women were safe, effective and well tolerated.

Authors+Show Affiliations

Erasmus Medisch Centrum, Dr.Molewaterplein 40, 3015 GD Rotterdam.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

dut

PubMed ID

15553999

Citation

Tempelman, C, et al. "[Highly Active Antiretroviral Therapy (HAART) in HIV-positive Pregnant Women in the Netherlands, 1997-2003: Safe, Effective and With Few Side Effects]." Nederlands Tijdschrift Voor Geneeskunde, vol. 148, no. 41, 2004, pp. 2021-5.
Tempelman C, Timmermans S, Godfried MH, et al. [Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects]. Ned Tijdschr Geneeskd. 2004;148(41):2021-5.
Tempelman, C., Timmermans, S., Godfried, M. H., Dieleman, J. P., Boer, K., & van der Ende, M. E. (2004). [Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects]. Nederlands Tijdschrift Voor Geneeskunde, 148(41), 2021-5.
Tempelman C, et al. [Highly Active Antiretroviral Therapy (HAART) in HIV-positive Pregnant Women in the Netherlands, 1997-2003: Safe, Effective and With Few Side Effects]. Ned Tijdschr Geneeskd. 2004 Oct 9;148(41):2021-5. PubMed PMID: 15553999.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects]. AU - Tempelman,C, AU - Timmermans,S, AU - Godfried,M H, AU - Dieleman,J P, AU - Boer,K, AU - van der Ende,M E, PY - 2004/11/24/pubmed PY - 2004/12/17/medline PY - 2004/11/24/entrez SP - 2021 EP - 5 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 148 IS - 41 N2 - OBJECTIVE: To assess the side effects, safety and efficacy of highly active antiretroviral therapy (HAART) in a cohort of HIV-infected pregnant women in the Netherlands. DESIGN: Retrospective. METHOD: Data were collected from the medical records of HIV-infected pregnant women who received HAART during pregnancy in the period 1 January 1997-1 June 2003 at 14 HIV-specialized centres in the Netherlands. The inclusion criteria were at least a triple drug regimen and birth at 20 or more weeks of gestation. Information was collected about patient characteristics, HAART prescribed, side effects, viral load response, mode of delivery and HIV-status of the neonate. RESULTS: A total of 267/413 women satisfied the inclusion criteria. Most women (n = 199) had not previously received anti-retroviral therapy and started HAART between weeks 21 and 28 of the pregnancy. The two most frequently used regimens contained nelfinavir (57%) or nevirapine (31%). Gastrointestinal side effects were more frequently observed in the nelfinavir group, while rash and hepatotoxicity were more frequently reported in the nevirapine group. Efficacy and pregnancy outcome were similar in both groups. Two infants (0.7%) were HIV-infected. CONCLUSION: HAART regimens containing nelfinavir or nevirapine in HIV-infected pregnant women were safe, effective and well tolerated. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/15553999/[Highly_active_antiretroviral_therapy__HAART__in_HIV_positive_pregnant_women_in_the_Netherlands_1997_2003:_safe_effective_and_with_few_side_effects]_ L2 - https://www.diseaseinfosearch.org/result/9735 DB - PRIME DP - Unbound Medicine ER -